1. Hepatitis C treatment outcomes using interferon- and ribavirin-based therapy in Kigali, Rwanda.
- Author
-
Riedel, David J., Taylor, Simone, Simango, Raulina, Kiromera, Athanase, Sebeza, Jackson, Baribwira, Cyprien, and Musabeyezu, Emmanuel
- Subjects
HEPATITIS C treatment ,HEPATITIS C virus ,INTERFERONS ,RIBAVIRIN ,ANTIVIRAL agents ,ANTIMETABOLITES - Abstract
Background: Hepatitis C virus (HCV) treatment data in sub-Saharan Africa are limited. This study was to determine HCV sustained virologic response(SVR) at 24 weeks in patients undergoing HCV therapy in Kigali, Rwanda. Methods: The paper presents data for all patients treated for HCV with ribavirin/interferon at King Faisal Hospital in Kigali, Rwanda, from 1 January 2007 to 31 December 2014. Results and Conclusions: There were 69 evaluable patients. HCV genotype 4(61%, 42/69) predominated. 24-week SVR was 70%(26/37) by per-protocol and 32%(26/69) by intention-to-treat analysis. HCV treatment in Rwanda is feasible. SVR with interferon/ribavirin was acceptable in the per-protocol analysis. Transition to newer direct acting antivirals is urgently needed in Rwanda and sub-Saharan Africa more generally to improve treatment outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF